{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:22:58Z","timestamp":1791138178331,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T00:00:00Z","timestamp":1395360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T00:00:00Z","timestamp":1395360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10637-014-0082-9","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T05:45:56Z","timestamp":1395294356000},"page":"670-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"32","author":[{"given":"Jordi","family":"Rodon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja J","family":"De Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Homji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Di Tomaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Sarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Trandafir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Massacesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,21]]},"reference":[{"issue":"8","key":"82_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627\u2013644","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"82_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0929-6646(09)60051-6","volume":"108","author":"WC Huang","year":"2009","unstructured":"Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108(3):180\u2013194","journal-title":"J Formos Med Assoc"},{"issue":"Suppl 3","key":"82_CR3","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.3816\/CBC.2010.s.015","volume":"10","author":"R Nahta","year":"2010","unstructured":"Nahta R, O\u2019Regan RM (2010) Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K\/Akt\/mTOR pathway. Clin Breast Cancer 10(Suppl 3):S72\u2013S78","journal-title":"Clin Breast Cancer"},{"issue":"33","key":"82_CR4","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452\u20134461","journal-title":"J Clin Oncol"},{"issue":"1","key":"82_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4161\/cbt.8.1.7209","volume":"8","author":"IK Kolasa","year":"2009","unstructured":"Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J et al (2009) PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8(1):21\u201326","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"82_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075\u20131083","journal-title":"J Clin Oncol"},{"issue":"7216","key":"82_CR7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"The Cancer Genome Atlas Research Network","year":"2008","unstructured":"The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061\u20131068","journal-title":"Nature"},{"issue":"7417","key":"82_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"PS Hammerman","year":"2012","unstructured":"Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R et al (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519\u2013525","journal-title":"Nature"},{"issue":"7418","key":"82_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","journal-title":"Nature"},{"issue":"2","key":"82_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D et al (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2):317\u2013328","journal-title":"Mol Cancer Ther"},{"key":"82_CR11","doi-asserted-by":"crossref","unstructured":"Koul D, Shen R, LaFortune TA, Tiao N, Kim YW, Liu JL et al (2010) NVP-BKM120: a selective pan-PI3 kinase inhibitor induces G2\/M arrest in glioma cell lines via FOXO3a and GADD45a loop. American Association for Cancer Research Congress. [abstract 350]","DOI":"10.1158\/1538-7445.AM10-350"},{"key":"82_CR12","doi-asserted-by":"crossref","unstructured":"Schnell CR, Arnal S, Becquet M, Allegrini P, Voliva C, Cozens R et al (2010) NVP-BKM120, a pan class I PI3K inhibitor impairs microvascular permeability and tumor growth as detected by DCE-MRI and IFP measurements via radio-telemetry: comparison with NVP-BEZ235. American Association for Cancer Research Congress. [abstract 4472]","DOI":"10.1158\/1538-7445.AM10-4472"},{"key":"82_CR13","doi-asserted-by":"crossref","unstructured":"Maira M, Menezes D, Pecchi S, Shoemaker K, Burger M, Schnell C et al (2010) NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I\/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models. AACR Meeting Abstracts. 4497 (abstract)","DOI":"10.1158\/1538-7445.AM10-4497"},{"key":"82_CR14","doi-asserted-by":"crossref","unstructured":"Voliva CF, Pecchi S, Burger M, Nagel T, Schnell C, Fritsch C et al (2010) Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I\/II clinical trials. AACR Meeting Abstracts 4498 (abstract)","DOI":"10.1158\/1538-7445.AM10-4498"},{"issue":"3","key":"82_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282\u2013290","journal-title":"J Clin Oncol"},{"issue":"10","key":"82_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092\u20131097","journal-title":"Arch Intern Med"},{"issue":"9","key":"82_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606\u2013613","journal-title":"J Gen Intern Med"},{"issue":"10","key":"82_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S (1998) Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17(10):1103\u20131120","journal-title":"Stat Med"},{"issue":"13","key":"82_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. european organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer 35(13):1773\u20131782","journal-title":"Eur J Cancer"},{"issue":"7091","key":"82_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature04694","volume":"441","author":"LC Foukas","year":"2006","unstructured":"Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091):366\u2013370","journal-title":"Nature"},{"issue":"2","key":"82_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85\u201396","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"82_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733\u2013747","journal-title":"Cell"},{"issue":"15_suppl","key":"82_CR23","first-page":"2541","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, LoRusso P, Tibes R, Shapiro G, Weiss GJ, Ware JA et al (2010) A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. ASCO Meeting Abstracts 28(15_suppl):2541","journal-title":"ASCO Meeting Abstracts"},{"issue":"15_suppl","key":"82_CR24","first-page":"3066","volume":"29","author":"JD Peyton","year":"2011","unstructured":"Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J et al (2011) A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. ASCO Meeting Abstracts 29(15_suppl):3066","journal-title":"ASCO Meeting Abstracts"},{"key":"82_CR25","doi-asserted-by":"crossref","unstructured":"Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J et al (2011) A first-in-human phase I study to evaluate GDC-0980, an oral PI3K\/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 29(suppl):abstract 3020 (poster presentation)","DOI":"10.1200\/jco.2011.29.15_suppl.3020"},{"key":"82_CR26","doi-asserted-by":"crossref","unstructured":"Munster PN, van der Noll R, Voest EE, Dees EC, Tan AR, Specht JM et al (2011) Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). ASCO Meeting Abstracts 29(15_suppl):3018","DOI":"10.1200\/jco.2011.29.15_suppl.3018"},{"issue":"6","key":"82_CR27","doi-asserted-by":"publisher","first-page":"e39626","DOI":"10.1371\/journal.pone.0039626","volume":"7","author":"P Nanni","year":"2012","unstructured":"Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML et al (2012) Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(\u2212\/\u2212);Il2rg(\u2212\/\u2212) mice and treatment with PI3K inhibitor. PLoS One 7(6):e39626","journal-title":"PLoS One"},{"issue":"1","key":"82_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.braindev.2008.04.006","volume":"31","author":"C Tohda","year":"2009","unstructured":"Tohda C, Nakanishi R, Kadowaki M (2009) Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev 31(1):69\u201374","journal-title":"Brain Dev"},{"issue":"5\u20136","key":"82_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1159\/000185557","volume":"22","author":"TF Ackermann","year":"2008","unstructured":"Ackermann TF, Hortnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F et al (2008) Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 22(5\u20136):735\u2013744","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"82_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pharmthera.2005.10.014","volume":"110","author":"HO Kalkman","year":"2006","unstructured":"Kalkman HO (2006) The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 110(1):117\u2013134","journal-title":"Pharmacol Ther"},{"key":"82_CR31","unstructured":"A phase I dose escalation study of BKM120 with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma - ClinicalTrials.gov (NCT01473901) [homepage on the Internet]. [cited 4\/3\/2013]"},{"key":"82_CR32","unstructured":"Safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab - ClinicalTrials.gov (NCT01132664) [homepage on the Internet]. [cited 4\/3\/2013]"},{"issue":"3","key":"82_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00259-011-1981-z","volume":"39","author":"N Mortazavi-Jehanno","year":"2012","unstructured":"Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, Le Stanc E, Edeline V et al (2012) Assessment of response to endocrine therapy using FDG PET\/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 39(3):450\u2013460","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"82_CR34","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1158\/1078-0432.CCR-10-2763","volume":"17","author":"L Mileshkin","year":"2011","unstructured":"Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ et al (2011) Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 17(10):3304\u20133315","journal-title":"Clin Cancer Res"},{"issue":"14","key":"82_CR35","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1200\/JCO.2011.39.1938","volume":"30","author":"GA McArthur","year":"2012","unstructured":"McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB et al (2012) Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30(14):1628\u20131634","journal-title":"J Clin Oncol"},{"issue":"11","key":"82_CR36","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","volume":"2","author":"A Juvekar","year":"2012","unstructured":"Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J et al (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer. Cancer Discov 2(11):1048\u20131063","journal-title":"Cancer Discov"},{"issue":"7","key":"82_CR37","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.nucmedbio.2012.04.006","volume":"39","author":"CJ Kelly","year":"2012","unstructured":"Kelly CJ, Hussien K, Muschel RJ (2012) 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition. Nucl Med Biol 39(7):986\u2013992","journal-title":"Nucl Med Biol"},{"issue":"8","key":"82_CR38","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1172\/JCI37539","volume":"120","author":"F Di Nicolantonio","year":"2010","unstructured":"Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120(8):2858\u20132866","journal-title":"J Clin Invest"},{"issue":"1","key":"82_CR39","doi-asserted-by":"publisher","first-page":"R9","DOI":"10.1186\/bcr3601","volume":"16","author":"BN Rexer","year":"2014","unstructured":"Rexer BN, Chanthaphaychith S, Dahlman KB, Arteaga CL (2014) Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res 16(1):R9","journal-title":"Breast Cancer Res"},{"key":"82_CR40","doi-asserted-by":"crossref","unstructured":"Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD et al (2012) In: BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=d14acbff-7602-45e9-a577-11db6325068e&cKey=04a16b3b-4956-4cf9-833f-b223331f46b4&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}. p. Abstract nr CT-01","DOI":"10.1158\/1538-7445.AM2012-CT-01"},{"key":"82_CR41","doi-asserted-by":"crossref","unstructured":"Huang A, Fritsch C, Wilson C, Reddy A, Liu M, Lehar J et al (2012) Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR Abstract nr 3749","DOI":"10.1158\/1538-7445.AM2012-3749"},{"issue":"7205","key":"82_CR42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","volume":"454","author":"S Jia","year":"2008","unstructured":"Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776\u2013779","journal-title":"Nature"},{"issue":"35","key":"82_CR43","doi-asserted-by":"publisher","first-page":"13057","DOI":"10.1073\/pnas.0802655105","volume":"105","author":"S Wee","year":"2008","unstructured":"Wee S, Wiederschain D, Maira SM, Loo A, Miller C, de Beaumont R et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105(35):13057\u201362","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"82_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1200\/JCO.2011.39.6390","volume":"30","author":"D Juric","year":"2012","unstructured":"Juric D, Baselga J (2012) Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 30(8):765\u2013766","journal-title":"J Clin Oncol"},{"issue":"8","key":"82_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550\u2013562","journal-title":"Nat Rev Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0082-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0082-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:50:23Z","timestamp":1678510223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,21]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0082-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,21]]},"assertion":[{"value":"17 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}